The FDA just released a safety warning that the gout medication, Uloric (febuxostat) brings an increased risk of heart-related deaths and injuries. This comes after the FDA already flagged the medication in the July for unreported drug interactions.
About Uloric
Uloric, manufactured by Takeda Pharmaceuticals, is a once-daily oral medication that treats gout. High levels of uric acid cause gout, which is a chronic and painful medical condition of the joints. It normally affects the toes. Uloric first came on the market in February 2009. It was the first new gout medication in over 40 years. However, soon people began to come forward saying that Takeda was not reporting severe side effects caused by Uloric.
New FDA Uloric Warning
When the FDA approved Uloric, the organization did it on the contingency that Takeda continues to study the after effects. Takeda just provided the FDA with the preliminary results of the 6,000 patient study. The primary outcome was a combination of heart-related death, nonfatal myocardial infarction, nonfatal stroke, and cardiac ischemia requiring urgent surgery. These results caused the FDA release a safety warning.
“The preliminary results show that overall, febuxostat did not increase the risk of these combined events compared to allopurinol. However, when the outcomes were evaluated separately, febuxostat showed an increased risk of heart-related deaths and death from all causes,” the FDA said.
We Want to Help Uloric Victims
If Uloric caused a heart-related injury in you or a loved one, contact us today. We provide a free, no-obligation consultation. Compensation may be available. This could include medical expenses, as well as awards for your pain and emotional suffering. There is no obligation when you call. Let us bring you justice.
